Scientists are scrambling to find the cause for the sudden spike in human cases of avian influenza A (H5N6) in China to 21 during year-to-date 2021, from only five in 2020, reports say.
If you are not happy with the results below please do another search
50 search results for:
Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round, led by seed financier ARCH Venture Partners along with Sofinnova Partners. Additional investors were Eli Lilly and Company, MRL Ventures Fund, an early-stage fund run by Merck & Co., Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments.
The U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee is meeting Oct. 26 to discuss and recommend an emergency use authorization for the Pfizer-BioNTech vaccine for children 5 through 11 years of age.
Becton Dickinson and Co. has partnered with Amazon.com Inc. to begin shipment of a new at-home rapid Covid-19 test that can confirm results using an entirely automated smartphone app.
Democratic Party lawmakers holding up proposed drug pricing reforms are among the largest beneficiaries of the pharmaceutical industry’s push to stave off price cuts, a Reuters analysis of public lobbying and campaign data shows.
To fast-track the time to market and gain a competitive edge, pharmaceutical development companies are increasingly implementing single-use technologies (SUT).
AstraZeneca shared positive results from the company’s TOPAZ-1 Phase III trial on Imfinzi (durvalumab) in increasing the chances for survival in advanced biliary tract cancer patients when combined with standard-of-care chemotherapy regimens.
The U.S. Food and Drug Administration greenlit Xipere, the first suprachoroidal injectable medicine for macular edema associated with uveitis, co-developed by Clearside Biomedical and Bausch & Lomb.
Dupixent (dupilumab) scored the blockbuster medicine’s second study win in a week after Regeneron Pharmaceuticals and Sanofi revealed positive results from the second Phase III trial for the treatment of eosinophilic esophagitis (EoE).
Merck on Oct. 25 revealed positive results from two Phase III trials on a potential treatment for adults with HIV-1 infection and are virologically suppressed on different antiretroviral regimens (ART).